Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Virtual 3D Intraoperative Communication System for Orthopedic Oncology: A Feasibility Study

Head/Neck

Disease Sites: Head/Neck

Phase: N/A

Investigator: Topf, Michael

NCTID:

Protocol No: VICC-VDHAN23197

Learn More

Blood-based, Point-of-need Assessment of CAR-T Vector Load in DLBCL Patients Undergoing Axicabtagene Ciloleucel (axi-cel) Therapy: A Multi-Site Study

Lymphoma

Disease Sites: Lymphoma

Phase: N/A

Investigator: Oluwole, Olalekan

NCTID:

Protocol No: VICC-IDCTT23426

Learn More

Open-Label, Long-Term Safety and Efficacy Study of Mim8 in Participants with Haemophilia A with or without Inhibitors

Disease Sites: Not Available

Phase: III

Investigator: Wheeler, Allison

NCTID: NCT05685238

Protocol No: NCBH2401-FRONTIER4

Learn More

Open-Label Safety Study in Adults and Adolescents with Haemophilia A with and without FVIII Inhibitors Switching Directly from Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis

Disease Sites: Not Available

Phase: III

Investigator: Wheeler, Allison

NCTID: NCT05878938

Protocol No: NCBH2302-FRONTIER5

Learn More

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Multiple Cancer Types

The goal of this clinical study is to learn more about the long-term safety, effectiveness
and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel,
KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored
interventional studies.

Disease Sites: Hematologic, Leukemia, Lymphoma, Pediatric Leukemia, Pediatric Lymphoma

Phase: N/A

Investigator: Kassim, Adetola

NCTID: NCT05041309

Protocol No: VICCCTT2170

Learn More

Evaluation of Immunologic Response following COVID-19 Vaccination in Children, Adolescents, and Young Adults with Cancer

Pediatrics

This study evaluates immunologic response following COVID-19 vaccination in children, adolescents, and young adults with cancer. Vaccines work by stimulating the bodys immune cells to respond against a specific disease. The immune response produces protection from that disease. Effects from cancer and from treatments for cancer can reduce the bodys natural disease fighting ability (called immunity). Factors such as vaccine type, timing of vaccine dosing related to treatment for cancer and number of vaccine doses or boosts (extra vaccine shots) may strengthen or diminish the bodys protective immune response. This study may help researchers learn more about how the bodys immune system responds to the COVID-19 vaccine when the vaccination is given during or after cancer treatment.

Disease Sites: Pediatrics

Phase: N/A

Investigator: Esbenshade, Adam

NCTID: NCT05228275

Protocol No: COGACCL21C2

Learn More

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Multiple Cancer Types

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.

Disease Sites: Lymphoma, Miscellaneous, Pediatric Solid Tumors

Phase: N/A

Investigator: Borinstein, Scott

NCTID: NCT03155620

Protocol No: COGAPEC1621SC

Learn More